Publications by authors named "S Mattke"

Aims: To compare all-cause and Alzheimer's disease (AD)-related healthcare resource utilization (HCRU) by cognitive stage.

Methods And Materials: This retrospective study analyzed insurance claims data linked to electronic health records (01/01/2015-12/31/2021). Patients with ≥1 cognitive assessment (Mini-Mental State Examination or Montreal Cognitive Assessment) and ≥1 medical or pharmacy claim for an AD diagnosis or AD medications were included.

View Article and Find Full Text PDF

Background: Over 90% of individuals with mild cognitive impairment (MCI) may not receive a timely diagnosis. Understanding community-based practice patterns, where most individuals are seen, is critical to improving patient care.

Objective: To understand how patients with MCI and mild dementia due to Alzheimer's disease (AD) are diagnosed and managed in community-based settings, including the use of clinical and cognitive assessments, referrals to dementia-related specialties, and receipt of treatment.

View Article and Find Full Text PDF

New treatment options are emerging for chronic wounds, which represent a growing problem because of population ageing and increasing burden of chronic disease. While promising, the existing evidence for advanced modalities is commonly derived from small and/or poorly controlled studies and clear criteria for selecting patients, who are likely to benefit from these expensive options are lacking. In this study, we develop and validate a machine learning model to predict if a chronic wound, independent of etiology, is expected to heal within 12 weeks to identify cases in potential need of advanced treatment options.

View Article and Find Full Text PDF
Article Synopsis
  • Diagnosing Alzheimer's disease is tough for doctors, which can lead to delays in getting the right care for patients.
  • Blood tests that check for signs of Alzheimer's could help doctors find the disease earlier and treat it better, but there are still some big challenges to overcome.
  • A special group of leaders in Alzheimer's research is working on solutions, like creating better guidelines, training healthcare workers, and making sure patients understand their test results.
View Article and Find Full Text PDF
Article Synopsis
  • Blood-based biomarkers (BBMs) are new tests that help doctors check for Alzheimer's disease in a simpler and cheaper way than older methods like brain scans or spinal fluid tests.! -
  • A special group called the Global CEO Initiative on Alzheimer's Disease is suggesting two ways to use these BBMs: one for initial testing and another to confirm more serious cases.! -
  • Using BBMs can make it easier for doctors to diagnose Alzheimer's, which means that patients can start getting needed treatments faster.!
View Article and Find Full Text PDF